UBS Group
CPRX

UBS Group’s Catalyst Pharmaceutical CPRX Stock Holding History

UBS Group’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-500
Closed -$2K – 8526
2015
Q1 		$2K Buy
500
+200
+67% +$721 ﹤0.01% 8435
2014
Q4 		$1K Buy
+300
New +$823 ﹤0.01% 9527

Other funds holding CPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

UBS Group's CPRX Position: Q2 2026 in Review

UBS Group increased its Catalyst Pharmaceutical (CPRX) stake by 47% in Q2 2026, buying an estimated $13.8M and bringing the position to 1,453,726 shares worth $45.7M. The position accounts for 0.01% of the portfolio, ranked #1837.

UBS Group first reported a position in CPRX in Q2 2015 and has held it in 36 quarters since. 396 funds tracked by Wall St. Rank hold CPRX as of Q2 2026.

  • UBS Group held 1,453,726 shares of Catalyst Pharmaceutical worth $45.7M as of Q2 2026.
  • UBS Group bought 467,636 Catalyst Pharmaceutical shares in Q2 2026, an estimated $13.8M.
  • Catalyst Pharmaceutical made up 0.01% of UBS Group's portfolio in Q2 2026, its #1837 holding.
  • UBS Group first reported a position in Catalyst Pharmaceutical in Q2 2015 and has held it in 36 quarters since.
  • 396 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2026.

Based on UBS Group's 13F filing for Q2 2026, filed 13 Aug 2026.